Clinical Trial Update: Selumetinib in Combination With Gefitinib in NSCLC Patients [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial evaluating the combination of selumetinib and gefitinib in patients with non-small cell lung cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Gefitinib (Gefitinib)
• Selumetinib (selumetinib)

Snippet

Sponsor: National Taiwan University Hospital | Conditions: Non-small Cell Lung Cancer (NSCLC) | Phase 1, Phase 2 | Status: COMPLETED